Halozyme Therapeutics Stock Forecast

Stock Price Forecast

The 11 analysts with 12-month price forecasts for Halozyme Therapeutics stock have an average target of 78.18, with a low estimate of 56 and a high estimate of 92. The average target predicts an increase of 16.13% from the current stock price of 67.32.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$56	$78.18	$78	$92
Change	-16.82%	+16.13%	+15.86%	+36.66%

Analyst Ratings

The average analyst rating for Halozyme Therapeutics stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26
Strong Buy	3	3	3	4	4	4
Buy	4	4	4	4	3	3
Hold	4	5	5	5	4	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	12	12	13	11	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Robert Wasserman Benchmark	Benchmark	Strong Buy Maintains $75 → $90	Strong Buy	Maintains	$75 → $90	+33.69%	Feb 19, 2026
Mohit Bansal Wells Fargo	Wells Fargo	Hold Maintains $65 → $75	Hold	Maintains	$65 → $75	+11.41%	Feb 19, 2026
Brendan Smith TD Cowen	TD Cowen	Strong Buy Maintains $79 → $90	Strong Buy	Maintains	$79 → $90	+33.69%	Jan 8, 2026
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $90	Strong Buy	Reiterates	$90	+33.69%	Dec 19, 2025
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $90	Strong Buy	Reiterates	$90	+33.69%	Nov 28, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

1.79B

from 1.40B

28.24%

from 1.40B

Revenue Next Year

2.02B

from 1.79B

12.79%

from 1.79B

EPS This Year

8.18

from 2.56

219.39%

from 2.56

EPS Next Year

10.04

from 8.18

22.85%

from 8.18

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	443.31M	660.12M	829.25M	1.02B	1.40B	1.79B	2.02B
Revenue Growth	65.66%	48.91%	25.62%	22.44%	37.55%	28.24%	12.79%
EPS	2.74	1.44	2.10	3.43	2.56	8.18	10.04
EPS Growth	201.10%	-47.45%	45.83%	63.33%	-25.36%	219.39%	22.85%
Forward PE	-	-	-	-	-	8.23	6.70
No. Analysts	-	-	-	-	-	11	9

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	1.9B	2.1B
Avg	1.8B	2.0B
Low	1.7B	1.9B

Revenue Growth

Revenue Growth	2026	2027
High	33.4%	17.9%
Avg	28.2%	12.8%
Low	22.4%	6.9%

EPS Forecast

EPS	2026	2027
High	8.62	10.58
Avg	8.18	10.04
Low	7.71	9.29

EPS Growth

EPS Growth	2026	2027
High	236.7%	29.4%
Avg	219.4%	22.8%
Low	201.3%	13.6%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.